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ABSTRACT 
OBJECTIVE: There is lack of monitoring from the injury site to guide management of 
patients with acute traumatic spinal cord injury. Here we describe a bedside microdialysis 
monitoring technique for optimizing spinal cord perfusion and drug delivery at the injury site.  
METHODS: 14 patients were recruited within 72 hours of severe spinal cord injury. We 
inserted intradurally at the injury site a pressure probe, to monitor continuously spinal cord 
perfusion pressure, and a microdialysis catheter, to monitor hourly glycerol, glutamate, 
glucose, lactate and pyruvate. The pressure probe and microdialysis catheter were placed on 
the surface of the injured cord. 
RESULTS: Microdialysis monitoring did not cause serious complications. Spinal cord 
perfusion pressure 90 – 100 mmHg and tissue glucose >4.5 mM minimized metabolic 
derangement at the injury site. Increasing spinal cord perfusion pressure by ~10 mmHg, 
increased the entry of intravenously administered dexamethasone at the injury site three-fold.  
INTERPRETATION: This study determined the optimum spinal cord perfusion pressure 
and optimum tissue glucose concentration at the injury site. We also identified spinal cord 
perfusion pressure as a key determinant of drug entry into the injured spinal cord. Our 
findings challenge current guidelines, which recommend maintaining mean arterial pressure 
at 85 – 90 mmHg for a week after spinal cord injury. We propose that future drug trials for 
spinal cord injury include pressure and microdialysis monitoring to optimize spinal cord 
perfusion and maximize drug delivery at the injury site.  
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INTRODUCTION 
Traumatic spinal cord injury (TSCI) is a devastating condition that, each year, affects about 
15 – 40 people per million
1
. The surgical, anesthetic and neurointensive care unit 
management of patients with acute TSCI is variable
2,3
. To guide management, we recently 
developed a novel technique to continuously monitor intraspinal pressure (ISP) at the injury 
site and compute spinal cord perfusion pressure (SCPP)
4,5
. Intraoperatively, a pressure probe 
is inserted subdurally to measure ISP at the injury site, which is the same as intraparenchymal 
ISP
6
. Monitoring ISP and SCPP for up to a week is safe based on a review of 42 patients
7
.  
Data obtained from human
8,9
 and mouse
10
 studies show that, after TSCI, the injured 
spinal cord swells and becomes compressed against the dura. Three intradural compartments 
form (above, at and below the injury site) each with a different ISP
11
. The low SCPP at the 
injury site
5,8
 suggests that the injured spinal cord is ischemic. We showed that SCPP can be 
increased by increasing the mean arterial pressure with inotropes
5
 or by reducing ISP with 
expansion duroplasty
8
. It remains unclear whether increasing SCPP is beneficial for the 
injured spinal cord.  
Microdialysis is widely used to monitor brain metabolism in brain-injured patients
12
. 
Microdialysis catheters monitor hourly the levels of brain tissue glucose, lactate, pyruvate, 
glutamate and glycerol in the extracellular space. Low glucose, high lactate, high lactate-to-
pyruvate ratio (LPR) and high lactate-to-glucose ratio (LGR) indicate metabolic 
derangement
13-15
. Glutamate is released during ischemia and causes neuronal death 
(excitotoxicity) whereas glycerol is a marker for cell membrane lipid degradation
12
. 
Microdialysis has also been used to quantify penetration of drugs including vigabatrin
16
, 
metronidazole
17
 and cefotaxime
18
 into injured human brain. Microdialysis monitoring has not 
previously been used in TSCI patients. Here, we describe a simple technique for 
simultaneous bedside monitoring of SCPP and microdialysis at the injury site. This technique 
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was used to determine the SCPP and tissue glucose level that minimize the metabolic 
derangement at the injury site; these are termed the optimal SCPP and the optimal tissue 
glucose level, respectively. We also determined the effect of altering SCPP on the entry of 
intravenously administered drugs into the damaged spinal cord.  
  
MATERIALS AND METHODS 
Institutional research board approval. Approval for the Injured Spinal Cord Pressure 
Evaluation (ISCoPE) study, including the patient information sheet and consent form was 
obtained from the St George’s Joint Research Office and the National Research Ethics 
Service London – St Giles Committee (No. 10/H0807/23). The study conforms with The 
Code of Ethics of the World Medical Association (Declaration of Helsinki). 
 
Patient recruitment. Inclusion criteria are: 1. Severe TSCI defined as American spinal 
injuries association Impairment Scale (AIS) grade A, B or C; 2. Age 18 – 70 years; 3. Timing 
between TSCI and surgery not more than 72 hours. Exclusion criteria are: 1. Patient unable to 
consent; 2. Other major injuries or co-morbidities; 3 Penetrating TSCI. Surgery and early 
management took place at the neurosurgery unit of St. George’s Hospital. Recruitment into 
the study was discussed with all eligible patients and their families on admission, the patient 
information sheet was given and the consent form was signed by each patient. Recruitment 
for microdialysis monitoring was between May 2014 and September 2015. 
 
Insertion of ISP probe and microdialysis catheters. Following bony realignment and 
posterior fixation, the ISP probe (Codman Microsensor Transducer®, Depuy Synthes, Leeds, 
UK) and microdialysis catheter(s) (CMA61, CMA Microdialysis AB, Sweden) were 
tunnelled through skin into the wound cavity. We chose the CMA61 microdialysis catheter, 
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which has a 3 cm long membrane, long shaft and 20 kDa cut-off rather than the CMA70 or 
CMA71 brain catheters, which are too short to tunnel for spinal cord monitoring. Details of 
the CMA61 catheter are in the Supplement. Under the operating microscope, the dura and 
arachnoid membranes were opened one level below the injury (Fig. 1A). The ISP probe was 
inserted through the durotomy and placed under the arachnoid on the spinal cord surface. We 
inserted a microdialysis catheter at the injury site in 14 patients. The microdialysis catheter 
was inserted until the tip was at the site of maximal spinal cord swelling. The dural opening 
was sutured and supplemented with fibrin glue (Tisseel
®
, Baxter, UK). ISP probes and 
microdialysis catheters were secured to the skin with silk sutures. A wound drain was 
allowed to drain under gravity for a week. Patients were given 5,000 units dalteparin daily 
starting on the day after the surgery. Dalteparin was omitted 24 hours before removing the 
probes and wound drain. 
 
ISP and SCPP monitoring. The ISP probe was connected to a Codman ICP box linked via a 
ML221 amplifier to a PowerLab running LabChart v.7.3.5 (AD Instruments, Oxford, UK). 
Arterial blood pressure was recorded from a radial artery catheter connected to the Philips 
Intellivue MX800 bedside monitoring system (Philips, Guildford, UK) in turn connected to 
the PowerLab system. The ISP and arterial blood pressure signals were sampled at 1 kHz for 
up to seven days. LabChart was used to analyse the signals and compute SCPP, defined as 
mean arterial pressure minus ISP. 
  
Microdialysis monitoring. Microdialysis monitoring was started postoperatively in the 
neurointensive care unit. CNS perfusion fluid (CMA Microdialysis AB, Sweden) was 
perfused at a rate of 0.3 µL/min, unless otherwise stated, using the CMA106 or CMA107 
infusion pump (CMA Microdialysis AB, Sweden). The transit time from the microdialysis 
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membrane to the vial collection chamber is 24 minutes. Microdialysis vials were changed 
hourly, stored at 4 °C, and batched analysed up to 24 hours later using ISCUS Flex (CMA 
Microdialysis AB, Sweden). The first two samples from each patient were discarded to allow 
priming of the microdialysis catheter and stabilisation of the metabolite concentrations. All 
samples were analyzed for glucose, lactate, pyruvate, glycerol and glutamate. LPR and LGR 
were calculated. 100-fold changes in metabolite concentration, compared with the preceding 
hour, were excluded from analysis. After analysis, samples were stored at -80 °C. 
 
Patient assessments. Neurological examinations were done on admission and at two weeks 
postoperatively, i.e. before discharge to the rehabilitation facility. A CT and MRI of the 
whole spine were done on admission. Another CT was done within 48 hours of surgery to 
check screw and probe positions (Fig. 1B). MRI of the injured spinal cord was done at about 
2 weeks and at 6 – 12 months after surgery. 
 
Metabolite recovery. The extrapolation to zero flow method was used to determine 
metabolite recoveries
19
. Data were collected on the last day of monitoring when metabolite 
levels were stable. Flow rate was changed every 2 hours and samples were collected every 30 
minutes. The first sample of each 2-hour period was discarded to allow for the transit time of 
the microdialysis fluid from the exchange membrane to the vial. We used flow rates of 0.3, 
1.0, 2.0 and 5.0 µL/min. The experiment was repeated in three patients and the following 
equation was fitted to the data: R = 100×[1 – exp(-K/f)], where R is metabolite recovery, K 
is exchange membrane surface area times mass transport coefficient and f is flow rate19. 
 
Dexamethasone assay. In three TSCI patients, a bolus of 4 mg dexamethasone was given 
intravenously. Venous blood was withdrawn before giving dexamethasone (0 min) and at 10 
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minutes, 1, 2, 4 and 8 hours after dexamethasone administration. Blood was allowed to clot 
for 30 minutes at room temperature, tubes were centrifuged at 7,000 revolutions per minute 
for 10 minutes and sera were collected and stored at -80 °C. In each patient, a microdialysis 
catheter at the injury site was perfused at 0.3 µL/min and samples were collected hourly. The 
experiment was done with SCPP kept high. At 24 hours later, the experiment was repeated 
with SCPP kept low. Serum and microdialysis samples were analysed using an enzyme-
linked immunosorbent assay kit (IDELISA-F016, ID-Labs, London, ON, Canada) according 
to the manufacturer’s instructions. For serum dexamethasone concentration, we fitted the 
exponential decay equation Dt = Do×exp(-λt) where Dt is dexamethasone concentration at 
time t, Do is dexamethasone concentration at time 0 and λ is the exponential decay constant. 
Serum dexamethasone half-life was calculated as t1/2 = ln(2)/λ. We determined the Area 
Under the Curve at 0 – 8 hours (AUC0-8h) for serum and spinal cord dexamethasone. 
 
Statistics. We used http://mycurvefit.com to fit R = 100×[1 – exp(-K/f)] (extrapolation to 
zero flow) and Dt = Do×exp(-λt) (dexamethasone kinetics) to the data. Two-way ANOVA 
(XLSTAT Premium, Addinsoft, New York, USA) was used to model each metabolite 
concentration (first factor injury site vs. below and second factor hours, or first factor AIS A 
vs. B/C and second factor hours) and dexamethasone concentration (first factor high vs. low 
SCPP and second factor time). Statistical significance was P < 0.05*, 0.01**, 0.005
†
, 
0.001
††
, 0.0005
#
, 0.0001
##
. 
 
RESULTS 
Patient details. We recruited 14 consecutively admitted TSCI patients with mean age 38 
years (Table 1). After surgery, patients were kept in the neurointensive care unit throughout 
the monitoring period. Most (92.9 %) were male, most (57.1 %) had thoracic injuries and 
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most (71.4 %) had no motor or sensory response below the level of injury on admission (AIS 
A). TSCI resulted from a fall in 42.9 % and a road traffic accident in 57.1 %. Mean time from 
injury to surgery was 1.5 days after TSCI. 71.4 % patients had posterior spinal fixation with 
laminectomy and 28.6 % had posterior fixation without laminectomy. The duration of 
microdialysis monitoring ranged from less than a day to 6 days. On average, patients had 
microdialysis monitoring for 4 days. Within 2 weeks of surgery, 14.3 % patients improved 
from AIS A to B; AIS grade did not worsen in any patient. 
 
Metabolite recovery. Plots of metabolite concentration at different flow rates are in Fig. 1C. 
For each metabolite, there was excellent goodness-of-fit (r < -0.95) with the theoretical curve. 
Relative recoveries were calculated from the theoretical curves as the metabolite 
concentration at 0.3 µL/min divided by the estimated metabolite concentration at no flow. 
Our data indicate relative recoveries at 88 – 100 % (Fig. 1D). 
 
SCPP vs. metabolite levels. During the microdialysis monitoring period the average SCPP 
of all patients was 60 – 80 mmHg (Fig. 2A). Figs. 2B-E show the average daily metabolite 
concentrations, LPR and LGR at the injury site at different SCPPs. SCPP 90 – 100 mmHg 
was associated with the least abnormal metabolic profile i.e. lowest glutamate, highest 
glucose as well as lowest LPR and LGR. Below 90 – 100 mmHg the metabolism of the injury 
site progressively worsened, i.e. negative correlation between SCPP vs. glutamate, LPR or 
LGR and positive correlation between SCPP vs. glucose. SCPP > 100 mmHg was associated 
with more deranged metabolism at the injury site than SCPP 90 – 100 mmHg, i.e. higher 
glutamate, lower glucose, higher LPR and higher LGR. Glycerol concentration was high (~55 
mM) with SCPP below 60 – 70 mmHg and low (~40 mmM) with SCPP > 70 mmHg. There 
was no correlation between average daily metabolite concentrations, LPR or LGR at the 
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injury site vs. ISP (not shown). We also plotted tissue glucose concentration at the injury site 
vs. LPR (Fig. 2F). Tissue glucose concentration >4.5 mM was associated with the lowest 
LPR; below 4.5 mM, glucose concentration inversely correlated with LPR. Glucose 
concentration at the injury site was 35.5 ± 1.0 % of serum glucose. Fig. 2G shows the 
relationship between serum glucose and microdialysis glucose. The data suggest that, after 
TSCI, optimum SCPP is 90 – 100 mmHg and optimum tissue glucose is >4.5 mM. 
 
Metabolites in complete vs. incomplete injuries. In Fig. 3 we compare average daily 
metabolite concentrations, LPR and LGR for patients with complete (AIS A) vs. incomplete 
(AIS B/C) neurological deficit. Metabolism at the injury site was more deranged for AIS A 
than AIS B/C, with markedly higher glycerol, glutamate, lactate, pyruvate, LPR and LGR as 
well as lower glucose for AIS A. The differences in metabolite levels between AIS A vs. AIS 
B/C were more marked during the first 72 h after injury. Within 3 – 4 days, glycerol and 
glutamate concentrations were comparable in AIS A vs. AIS B/C patients, though lactate, 
pyruvate, LPR and LGR remained higher and glucose remained lower throughout the 
monitoring period in AIS A than AIS B/C. These findings suggest that the severity of TSCI 
correlates with the degree of metabolic disturbance at the injury site. 
 
Dexamethasone kinetics. The low and high SCPP time profiles following administration of 
dexamethasone are in Fig. 4A. Over 8 hours, mean low (SCPP (72 ± 1 mmHg, mean ± 
standard error) was significantly lower than mean high SCPP (84 ± 1 mmHg). The 
correlation coefficient of the dexamethasone standards curve was 0.99 and the assay 
coefficient of variation was 14 %. After administration of the 4 mg dexamethasone bolus, 
serum dexamethasone concentration decayed exponentially with no significant difference in 
dexamethasone concentrations between high vs. low SCPP. The correlation coefficient for the 
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best-fit exponential decay curve was -1.00 for high and low SCPP (Fig. 4B). The AUC0-
8h(serum) and t1/2 for serum dexamethasone were comparable at high vs. low SCPP: AUC0-
8h(serum) was 1,091 vs. 942 ng.h/mL and t1/2 was 2.1 vs. 2.3 hours. Significantly more 
dexamethasone entered the injured spinal cord at high vs. low SCPP with AUC0-8h(cord) at 17 
vs. 6 ng.h/mL and peak spinal cord concentration at 4.8 vs. 2.0 ng/mL (Fig. 4C). Only a small 
proportion of the intravenous dexamethasone entered the spinal cord with AUC0-
8h(cord)/AUC0-8h(serum) = 1.62 vs. 0.64 % at high vs. low SCPP. Therefore, increasing SCPP 
markedly increases the entry of dexamethasone from the blood into the injured spinal cord. 
 
Complications. Table 2 summarizes patient complications. On average, patients were 
followed up for 4.1 ± 1.1 months (mean ± standard error). There was no immediate 
postoperative deterioration in AIS grade. Probe-related complications, noted in 28.5 % 
patients, were asymptomatic pseudomeningocele or CSF leak through the probe skin exit site. 
All pseudomeningoceles resolved spontaneously and the CSF leak stopped after we sutured 
the skin. We did not observe meningitis, spinal cord damage or hematoma. Complications 
unrelated to the probes include pneumonia, vertebral artery dissection from the original 
trauma, superficial wound infection and a sacral pressure ulcer. One patient died from 
pulmonary embolism after he was discharged. In another T12 AIS B patient the mean arterial 
pressure dropped to 60 mmHg (SCPP 20 mmHg) for 35 minutes. He developed arm 
weakness and the sensory level ascended. When the SCPP was increased with 
norepinephrine, power in the arms normalized and the sensory level descended. 
 
DISCUSSION 
We showed that, in patients with acute TSCI, simultaneous monitoring of SCPP and 
microdialysis from the injury site is feasible and safe. The microdialysis catheter was easily 
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inserted during spinal fixation surgery and was removed in the neurointensive care unit. 
Complications related to the microdialysis catheter were minor; they include CSF leak from 
the catheter exit site that resolved by suturing the skin and asymptomatic pseudomeningocele 
that resolved spontaneously. Since our patient sample is small, complications may appear in a 
larger sample. Our microdialysis data suggest that the optimal SCPP is 90 – 100 mmHg and 
the optimal tissue glucose is more than 4.5 mM because these values minimize the metabolic 
derangement at the injury site. We also showed that simultaneous monitoring of SCPP and 
microdialysis could be used to enhance drug entry at the injury site. Based on our current 
findings and earlier studies4-9,20,21, a large-scale study of outcome from TSCI in patients who 
have monitoring vs. those who do not is warranted. 
 There are technical nuances. First, a long (3 cm) exchange membrane was inserted to 
achieve near complete metabolite recovery at 0.3 µL/min flow rate, compared with a 1 cm 
long microdialysis membrane at 0.3 µL/min, which only achieves 70 % metabolite 
recovery
22
. Second, we placed the microdialysis catheter under the arachnoid because 
diffusion across the arachnoid is limited by inter-cellular tight junctions
23
 and is greatly 
reduced for hydrophilic substances
24
. Third, we used surface rather than intraparenchymal 
microdialysis. Surface microdialysis was originally described in pig liver
25
 and myocardium
26
 
with excellent correlations between surface and intraparenchymal levels of lactate, glucose 
and glycerol. We advocate using surface rather than intraparenchymal microdialysis 
monitoring to minimize the risk of probe-related hematoma and mechanical spinal cord 
damage. 
We found more profound metabolic derangement in AIS A than AIS B/C patients. 
These findings suggest that the severity of TSCI correlates with the metabolic derangement at 
the injury site. A microdialysis study in a pig TSCI model concluded that the metabolic 
response at the injury site depends on the biomechanical nature of the injury
27
. Further 
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studies are required to determine if the metabolic derangement at the injury site accurately 
predicts AIS grade conversion after TSCI. 
Microdialysis was used to characterize the relationship between SCPP, ISP, glucose 
and metabolism at the injury site. SCPP pressure below 70 mmHg was associated with cell 
lysis (high glycerol). As SCPP increased to 90 – 100 mmHg, metabolism improved (lower 
glutamate and lactate, lower LPR and LGR and higher glucose). Interestingly, when SCPP 
increased above 100 mmHg the metabolic profile worsened (higher glutamate and lactate, 
higher LPR and LGR and lower glucose). Therefore, not only hypoperfusion (SCPP below 90 
mmHg), but also hyperperfusion (SCPP above 100 mmHg) may be detrimental for the 
injured spinal cord. This is consistent with our earlier report of a U-shaped relationship 
between the spinal pressure reactivity index and SCPP, which also indicated optimum SCPP 
around 90 mmHg
5,8,21
. After TSCI, ISP is 20 – 30 mmHg and therefore SCPP 90 – 100 
mmHg corresponds to mean arterial pressure 110 – 130 mmHg. Our findings thus challenge 
current guidelines, which recommend maintaining mean arterial pressure at 85 – 90 mmHg 
for a week after TSCI28. Elevating mean arterial pressure after TSCI requires inotropic 
support, which is associated with several complications29. To reduce inotrope requirements 
and, therefore, inotrope-related complications when aiming for SCPP 90 – 100 mmHg, 
expansion duroplasty could be performed to lower the ISP8. No clear correlation was found 
between ISP and metabolite levels at the injury site; therefore, unlike changes in SCPP, 
changes in ISP may not be detrimental for the injured spinal cord. The microdialysis data also 
showed that the optimum glucose level at the injury site is more than 4.5 mM because this 
minimizes the LPR. Since acute hyperglycemia impairs functional improvement after TSCI
30
, 
it may be safer to elevate the tissue glucose concentration at the injury site by increasing the 
SCPP rather than by increasing the serum glucose concentration. Future studies employing 
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rapid sampling microdialysis may determine if the optimum SCPP and optimum tissue 
glucose concentration vary between TSCI patients.  
 We showed that SCPP is a major determinant of drug entry into the injured spinal 
cord. The serum half-life of dexamethasone was 2 – 3 hours, in agreement with earlier 
studies
31
. By increasing SCPP by about 10 mmHg, we increased dexamethasone entry into 
the injured spinal cord three-fold. Completed
32,33
 and on-going
34,35
 trials of neuroprotective 
drugs in TSCI do not monitor SCPP or drug entry at the injury site. Our data suggest that 
failure to optimize SCPP and drug delivery at the injury site may lead to the erroneous 
conclusion that the tested drug does not improve outcome after TSCI, even if the drug is 
neuroprotective. A way to increase drug entry at the injury site is by localized delivery 
through the microdialysis catheter 
36
. Given the spatial limitations of microdialysis, further 
studies employing several microdialysis catheters are required to compare drug entry at the 
injury site vs. the penumbra. 
 We conclude that multi-modality monitoring from the injury site after TSCI is helpful 
for guiding clinical management to reduce secondary damage. Further studies are needed to 
determine if interventions to optimize SCPP and tissue metabolite levels improve outcome. 
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FIGURE LEGENDS 
 
Fig. 1. Insertion of microdialysis catheter at injury site and metabolite recovery. A. i. 
Insertion of ISP probe and microdialysis (MD) catheter under dura and arachnoid. ii. 
Magnified view of dural entry site. Arrowheads show arachnoid. iii. Sutured dural entry site. 
iv. Prone patient with cervical TSCI at end of surgery. S, screw; ISP, intraspinal pressure 
probe. B. Coronal postoperative CT scan through injury site. C. Plots of metabolite 
concentration vs. flow rate and best-fit theoretical curve. Mean ± standard error. r = 
correlation coefficient. D. Percent recovery at flow rate 0.3 µL/min. 
 
Fig. 2. Metabolite concentrations at injury site at different SCPPs. A. Mean hourly SCPP 
vs. time. B. Glycerol, C. Glutamate, D. Glucose, Lactate, Pyruvate, E. LGR and LGR vs. 
mean hourly SCPP. F. Glucose vs. LPR. G. Serum glucose vs. microdialysis glucose. B – G 
include the metabolite measurements obtained throughout the monitoring period from all 
patients. Mean ± standard error. 
 
Fig. 3. Metabolite concentrations at injury site of AIS A vs. AIS B/C patients. A. 
Glycerol, B. Glutamate, C. Glucose, D. Pyruvate, E. Lactate, F. LPR, and G. LGR. Mean ± 
standard error. 10 AIS A vs. 4 AIS B/C patients. Mean ± standard error; P < 0.01**, 0.0001
##
 
 
Fig. 4. Effect of SCPP on penetration of dexamethasone into injured spinal cord. A 4 mg 
bolus of dexamethasone was given intravenously at time 0 at low SCPP. After 24 h, another 4 
mg dexamethasone bolus was given intravenously at time 0 at high SCPP. A. High and low 
SCPP during the experiment. Concentration of dexamethasone B. in serum, and C. at injury 
site at high and low SCPP. Mean ± standard error; NS, not significant; P < 0.05*, 0.0001
##
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Table 1. Patient characteristics. 
Number of patients 14 
Mechanism of injury (number of patients) Fall (6), Road traffic accident (8) 
Age in years, mean (range) 38 (19 – 70) 
Male : female 13 : 1 
Pre-operative AIS (number of patients) A (10), B (3), C (1) 
AIS at 2 weeks after surgery (number of patients) A (8), B (5), C (1) 
Level of injury (number of patients) Cervical (6), Thoracic (8) 
Hours to surgery, mean (range) 36.5 (9 – 72) 
Laminectomy? (number of patients) Yes (10), No (4) 
Hours of microdialysis monitoring, mean (range) 100 (19 – 145) 
AIS = American spinal injuries association Impairment Scale 
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Table 2. Complications in patients who had microdialysis monitoring. 
COMPLICATION NO. OF PATIENTS % 
Associated with microdialysis catheter    
CSF leak
a
 1 7.1 
Asymptomatic pseudomeningocele
b
 3 21.4 
Probe associated hematoma
c
 0 0.0 
Meningitis 0 0.0 
Not associated with microdialysis catheter   
Death
d
 1 7.1 
Pneumonia 10 71.4 
Traumatic vascular injury
e
 1 7.1 
Hypotension causing spinal cord ischemia
f
 1 7.1 
Superficial wound infection
g 
 1 7.1 
Pressure ulcer 1 7.1 
a
Resolved by suturing microdialysis catheter exit site. 
b
MRI at 2 weeks. Pseudomeningoceles resolved on MRI at 
6 – 12 months. 
c
MRI from 11/14 patients. 
d
Patient died from pulmonary embolus at 28 days at a different 
hospital. 
e
Vertebral artery dissection. 
f
T12 TSCI AIS B. The sensory level ascended from L1 to T5 on day 3 
during hypotensive episode (mean arterial pressure 60 mmHg, SCPP 20 mmHg for 35 min). MRI showed spinal 
cord ischemia at T4. At 2 weeks the sensory level improved and AIS grade was B. 
g
Resolved with antibiotics. 
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